MCID: ERY017
MIFTS: 46

Erythema Elevatum Diutinum

Categories: Bone diseases, Cardiovascular diseases, Rare diseases, Skin diseases

Aliases & Classifications for Erythema Elevatum Diutinum

MalaCards integrated aliases for Erythema Elevatum Diutinum:

Name: Erythema Elevatum Diutinum 12 53 59 44 15 73

Characteristics:

Orphanet epidemiological data:

59
erythema elevatum diutinum
Age of onset: All ages; Age of death: normal life expectancy;

Classifications:



External Ids:

Disease Ontology 12 DOID:0060567
ICD10 33 L95.1
MeSH 44 C535509
SNOMED-CT 68 58872001
Orphanet 59 ORPHA90000
ICD10 via Orphanet 34 L95.1
MESH via Orphanet 45 C535509
UMLS via Orphanet 74 C0263398
UMLS 73 C0263398

Summaries for Erythema Elevatum Diutinum

NIH Rare Diseases : 53 Erythema elevatum diutinum is a rare type of chronic cutaneous vasculitis characterized by red, purple, brown or yellow papules, plaques (thick, red patches of skin), or nodules.These lesions are located mainly on the knees, elbows, hands, feet, face, genitals and buttocks. Although it is a chronic condition, most cases respond well to treatment with dapsone. The cause of this condition remains unknown. 

MalaCards based summary : Erythema Elevatum Diutinum is related to systemic lupus erythematosus and vasculitis. An important gene associated with Erythema Elevatum Diutinum is CXCL8 (C-X-C Motif Chemokine Ligand 8), and among its related pathways/superpathways are Innate Immune System and NF-kappaB Signaling. The drugs Heparin and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include skin, bone and neutrophil, and related phenotypes are arthralgia and abnormal blistering of the skin

Disease Ontology : 12 A vasculitis characterised by red, purple, brown or yellow papules (raised spot), plaques, or nodules, found on the backs of the hands, other extensor surfaces overlying joints, and on the buttocks.

Wikipedia : 76 Erythema elevatum diutinum is a form of... more...

Related Diseases for Erythema Elevatum Diutinum

Diseases related to Erythema Elevatum Diutinum via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 138)
# Related Disease Score Top Affiliating Genes
1 systemic lupus erythematosus 29.5 CXCL8 FOXP3 GATA3 S100A9 TBX21 TNFRSF1B
2 vasculitis 10.7
3 arthritis 10.6
4 pyoderma 10.6
5 rheumatoid arthritis 10.5
6 pyoderma gangrenosum 10.5
7 myelodysplastic syndrome 10.5
8 dermatitis 10.4
9 celiac disease 1 10.3
10 dermatitis herpetiformis, familial 10.3
11 crohn's disease 10.3
12 leukemia 10.3
13 lymphoma 10.3
14 sarcoma 10.3
15 scleritis 10.3
16 relapsing polychondritis 10.3
17 human immunodeficiency virus infectious disease 10.3
18 dermatitis herpetiformis 10.3
19 lupus erythematosus 10.3
20 spondyloarthropathy 1 10.2
21 leukemia, chronic lymphocytic 2 10.2
22 leukemia, chronic lymphocytic 10.2
23 porphyria cutanea tarda 10.2
24 myasthenia gravis 10.2
25 hypereosinophilic syndrome, idiopathic 10.2
26 neutrophilic dermatosis, acute febrile 10.2
27 leukemia, chronic myeloid 10.2
28 b-cell lymphomas 10.2
29 diabetes mellitus 10.2
30 hepatitis 10.2
31 hepatitis b 10.2
32 keloids 10.2
33 lymphedema 10.2
34 ulcerative colitis 10.2
35 cutaneous lupus erythematosus 10.2
36 erythema multiforme 10.2
37 colitis 10.2
38 dermatomyositis 10.2
39 lymphocytic leukemia 10.2
40 pseudopterygium 10.2
41 panuveitis 10.2
42 pancytopenia 10.2
43 porphyria 10.2
44 poems syndrome 10.2
45 hypothyroidism 10.2
46 panniculitis 10.2
47 urticaria 10.2
48 squamous cell carcinoma 10.2
49 palmoplantar keratosis 10.2
50 verrucous carcinoma 10.2

Graphical network of the top 20 diseases related to Erythema Elevatum Diutinum:



Diseases related to Erythema Elevatum Diutinum

Symptoms & Phenotypes for Erythema Elevatum Diutinum

Human phenotypes related to Erythema Elevatum Diutinum:

59 32 (show all 8)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 arthralgia 59 32 hallmark (90%) Very frequent (99-80%) HP:0002829
2 abnormal blistering of the skin 59 32 frequent (33%) Frequent (79-30%) HP:0008066
3 myalgia 59 32 occasional (7.5%) Occasional (29-5%) HP:0003326
4 skin rash 59 32 hallmark (90%) Very frequent (99-80%) HP:0000988
5 skin vesicle 59 32 frequent (33%) Frequent (79-30%) HP:0200037
6 increased antibody level in blood 59 32 frequent (33%) Frequent (79-30%) HP:0010702
7 skin nodule 59 32 occasional (7.5%) Occasional (29-5%) HP:0200036
8 vasculitis in the skin 59 32 hallmark (90%) Very frequent (99-80%) HP:0200029

GenomeRNAi Phenotypes related to Erythema Elevatum Diutinum according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.02 CD34 CXCL8 F13A1 S100A9 TNFRSF1B

MGI Mouse Phenotypes related to Erythema Elevatum Diutinum:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.91 CD34 CD68 F13A1 FOXP3 GATA3 PECAM1
2 homeostasis/metabolism MP:0005376 9.76 CD34 F13A1 FOXP3 GATA3 PECAM1 S100A9
3 digestive/alimentary MP:0005381 9.72 FOXP3 GATA3 PECAM1 TBX21 TNFRSF1B
4 immune system MP:0005387 9.56 CD34 CD68 FOXP3 GATA3 PECAM1 S100A9
5 respiratory system MP:0005388 9.02 F13A1 FOXP3 PECAM1 TBX21 TNFRSF1B

Drugs & Therapeutics for Erythema Elevatum Diutinum

Drugs for Erythema Elevatum Diutinum (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 264)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Heparin Approved, Investigational Phase 4,Phase 3 9005-49-6 772 46507594
2
leucovorin Approved Phase 4,Phase 3,Phase 2 58-05-9 6006 143
3
Methotrexate Approved Phase 4,Phase 3,Phase 2 59-05-2, 1959-05-2 126941
4
Budesonide Approved Phase 4 51333-22-3 63006 5281004
5
Canagliflozin Approved Phase 4 842133-18-0
6
Insulin Aspart Approved Phase 4,Phase 3 116094-23-6 16132418
7
Insulin Glargine Approved Phase 4 160337-95-1
8
Zinc Approved, Investigational Phase 4,Phase 3 7440-66-6
9
Metformin Approved Phase 4,Phase 3,Phase 2 657-24-9 14219 4091
10
Insulin glulisine Approved Phase 4 207748-29-6
11
Pioglitazone Approved, Investigational Phase 4,Phase 3 111025-46-8 4829
12
Repaglinide Approved, Investigational Phase 4 135062-02-1 65981
13
Nateglinide Approved, Investigational Phase 4 105816-04-4 60026
14
Goserelin Approved Phase 4 65807-02-5 47725 5311128
15
Leuprolide Approved, Investigational Phase 4 53714-56-0 657181 3911
16
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 59-30-3 6037
17 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
18 Hormone Antagonists Phase 4,Phase 3,Phase 2
19 Hormones Phase 4,Phase 3,Phase 2
20 Immunologic Factors Phase 4,Phase 3,Phase 2
21 calcium heparin Phase 4,Phase 3
22 Vitamin B9 Phase 4,Phase 3,Phase 2
23 Antirheumatic Agents Phase 4,Phase 3,Phase 2
24 Vitamin B Complex Phase 4,Phase 3,Phase 2
25 Immunosuppressive Agents Phase 4,Phase 3,Phase 2
26 Folic Acid Antagonists Phase 4,Phase 3,Phase 2
27 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2
28 Folate Phase 4,Phase 3,Phase 2
29 Dermatologic Agents Phase 4,Phase 3,Phase 2
30 Antimetabolites Phase 4,Phase 3,Phase 2
31 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2
32 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2
33 Contraceptive Agents Phase 4,Phase 3,Phase 2
34 Adrenergic beta-Agonists Phase 4
35 Anti-Asthmatic Agents Phase 4,Phase 3
36 Adrenergic Agonists Phase 4,Phase 3
37 Autonomic Agents Phase 4,Phase 3,Phase 2
38 Adrenergic Agents Phase 4,Phase 3
39 Formoterol Fumarate Phase 4
40 Bronchodilator Agents Phase 4,Phase 3
41 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
42 glucocorticoids Phase 4,Phase 3,Phase 2
43 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
44 Adrenergic beta-2 Receptor Agonists Phase 4
45 Budesonide, Formoterol Fumarate Drug Combination Phase 4
46 Respiratory System Agents Phase 4,Phase 3
47 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
48 Immunoglobulins Phase 4,Phase 3,Phase 2
49 Antibodies, Monoclonal Phase 4,Phase 3
50 Antibodies Phase 4,Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 100)
# Name Status NCT ID Phase Drugs
1 Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX® as Compared to SYMBICORT® TURBOHALER® as Treatment for Adult Patients With Asthma Completed NCT02062463 Phase 4 Budesonide and formoterol fumarate dehydrate (BF) SPIROMAX;SYMBICORT TURBOHALER budesonide and formoterol fumarate
2 A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis. Completed NCT02752776 Phase 4 Secukinumab
3 A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus Completed NCT01989754 Phase 4 Placebo;Canagliflozin, 100 mg;Canagliflozin, 300 mg
4 Comparison of a Basal Plus One Insulin Regimen With a Biphasic Insulin Regimen in Type 2 Diabetes Patients Completed NCT00965549 Phase 4 INSULIN GLARGINE (HOE901);Insulin aspart;Insulin Glulisine
5 Local Phase 4 Pan-European SMART Study Completed NCT00463866 Phase 4 Budesonide/formoterol
6 AQUACEL® Ag Dressing and Urgotul® Silver Dressing on Healing of Chronic Venous Leg Ulcers Completed NCT01084577 Phase 4
7 A Pragmatic Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients (DECIDE Study) Recruiting NCT02616666 Phase 4 Dapagliflozin;Standard of Care
8 A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Severe Active Rheumatoid Arthritis, Comparing Tapering Versus Maintaining the Methotrexate Dosage Terminated NCT01661140 Phase 4 Methotrexate (stable dose);Tocilizumab;Methotrexate (tapering dose)
9 GP Extended Action Triptorelin Terminated NCT01673984 Phase 4 Decapeptyl® SR 22.5mg;Decapeptyl® SR 11.25mg; Prostap® 3 DCS 11.25mg; Zoladex® LA 10.8mg
10 Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine for Advanced Colorectal Cancer or Breast Cancer Unknown status NCT00559858 Phase 3
11 Intensity-Modulated Radiation Therapy in Treating Patients With Localized Prostate Cancer Unknown status NCT00392535 Phase 3 cyproterone acetate;releasing hormone agonist therapy
12 Dalteparin in Preventing Blood Clots in Patients With Lung Cancer Unknown status NCT00519805 Phase 3 dalteparin
13 Combination Chemotherapy With or Without Cetuximab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer Unknown status NCT00182715 Phase 3 capecitabine;fluorouracil;leucovorin calcium;oxaliplatin
14 Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation Completed NCT00412984 Phase 3 warfarin;apixaban
15 A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease Completed NCT00501059 Phase 3 Aspirin (Acetylsalicylic acid, BAYE4465);Placebo
16 Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain Completed NCT01337089 Phase 3 Nabiximols
17 Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer Completed NCT01262651 Phase 3 Nabiximols;Placebo (GA-0034)
18 High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention Completed NCT01355159 Phase 3 Folic Acid 4 mg;Placebo
19 A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C. Difficile-Associated Diarrhea Completed NCT00196794 Phase 3 Tolevamer potassium-sodium (GT267-004)
20 A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent Completed NCT02046603 Phase 3 Tocilizumab;DMARDs;Oral Corticosteroids;Methotrexate
21 Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension Completed NCT01788358 Phase 3 Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106);Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106);Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106);Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
22 Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Completed NCT01764633 Phase 3 Placebo
23 Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes Completed NCT01336023 Phase 3 insulin degludec/liraglutide;insulin degludec;liraglutide
24 Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease Completed NCT01313676 Phase 3 fluticasone furoate/vilanterol;fluticasone furoate;vilanterol
25 A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer Completed NCT01424566 Phase 3 Nabiximols;Placebo (GA-0034)
26 An Extension to Study MA21573, Evaluating Tocilizumab in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biological DMARDs and/or Anti-tumor Necrosis Factor (TNF) Therapy Completed NCT00883753 Phase 3 tocilizumab [RoActemra/Actemra]
27 An Exploratory Study of Tocilizumab in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Current Non-Biologic DMARDs and/or Anti-TNF Therapy. Completed NCT00750880 Phase 3 tocilizumab [RoActemra/Actemra]
28 Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM Completed NCT00736099 Phase 3 linagliptine 5 mg;linagliptine 5 mg and pioglitazone 30 mg
29 Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients Completed NCT00660907 Phase 3 dapagliflozin;glipizide;metformin hydrochloride
30 A Randomised Placebo Controlled Study of OXN PR for Severe Parkinson's Disease Associated Pain Completed NCT01439100 Phase 3 Oxycodone/Naloxone Prolonged Release tablets;Placebo
31 BI 1356 (Linagliptin) in Combination With Metformin and a Sulphonylurea in Type 2 Diabetes Completed NCT00602472 Phase 3 linagliptin;placebo
32 Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD) Completed NCT00400153 Phase 3 Atrovent Respimat (20 mcg);COMBIVENT MDI (36/206 mcg);Combivent Respimat (20 mcg/100 mcg);Placebo via corresponding inhaler for blinding purposes
33 Comparison of Insulin Detemir, Insulin Aspart and Biphasic Insulin Aspart 30 With OAD Treatment in Type 2 Diabetes Completed NCT00184600 Phase 3 biphasic insulin aspart;insulin detemir;insulin aspart
34 Dexmedetomidine Versus Propofol for Continuous Sedation in the Intensive Care Unit (ICU) Completed NCT00479661 Phase 3 Dexmedetomidine;Propofol
35 A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib Completed NCT01324596 Phase 3 Intravenous;Bortezomib
36 A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer Completed NCT00069121 Phase 3 capecitabine [Xeloda];Oxaliplatin;Oxaliplatin;Leucovorin;5 FU
37 Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism Completed NCT00633893 Phase 3 Apixaban;Placebo
38 Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Completed NCT00454480 Phase 2, Phase 3 arsenic trioxide;azacitidine;busulfan;clofarabine;cytarabine;daunorubicin hydrochloride;fludarabine phosphate;gemtuzumab ozogamicin;melphalan;tipifarnib
39 A Safety Extension Study of SHP647 in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA) Recruiting NCT03283085 Phase 3 25 mg SHP647;75 mg SHP647
40 Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis Recruiting NCT03259334 Phase 3 SHP647
41 Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours Recruiting NCT02804815 Phase 3 Aspirin 100mg;Aspirin 300mg;Placebo 100mg;Placebo 300mg
42 A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis Recruiting NCT03524092 Phase 3 Mirikizumab;Mirikizumab;Placebo
43 An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1) Recruiting NCT03518086 Phase 3 Mirikizumab;Placebo
44 Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year Recruiting NCT03464136 Phase 3
45 A Study of the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Recruiting NCT03105128 Phase 3 placebo for risankizumab;risankizumab IV;risankizumab SC
46 A Study of the Efficacy and Safety of Risankizumab in Subjects With Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991; or Completed M15-989 Recruiting NCT03105102 Phase 3 placebo for risankizumab SC;risankizumab IV;placebo for risankizumab IV;risankizumab SC
47 A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment Recruiting NCT03104413 Phase 3 placebo for risankizumab IV;risankizumab SC;risankizumab IV
48 Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease Recruiting NCT02914561 Phase 3 Filgotinib;Placebo to match filgotinib
49 Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis Recruiting NCT02914522 Phase 3 Filgotinib;Placebo to match filgotinib
50 A Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004 Recruiting NCT02615873 Phase 3 Accordion Pill™ Carbidopa/Levodopa

Search NIH Clinical Center for Erythema Elevatum Diutinum

Cochrane evidence based reviews: erythema elevatum diutinum

Genetic Tests for Erythema Elevatum Diutinum

Anatomical Context for Erythema Elevatum Diutinum

MalaCards organs/tissues related to Erythema Elevatum Diutinum:

41
Skin, Bone, Neutrophil, Liver, Thyroid, B Cells, Spleen

Publications for Erythema Elevatum Diutinum

Articles related to Erythema Elevatum Diutinum:

(show top 50) (show all 210)
# Title Authors Year
1
Erythema elevatum diutinum associated with severe oropharyngeal ulceration and pyoderma gangrenosum. ( 29750453 )
2018
2
Erythema Elevatum Diutinum Treated With Mycophenolate Mofetil. ( 29509562 )
2018
3
Erythema elevatum diutinum-like vasculitis secondary to cocaine adulterated with levamisole. ( 29423942 )
2018
4
Erythema elevatum diutinum with pustule formation: An unusual finding. ( 29292528 )
2018
5
Erythema elevatum diutinum verbunden mit schwerer oropharyngealer Ulzeration und Pyoderma gangraenosum. ( 29750450 )
2018
6
Late-stage nodular erythema elevatum diutinum mimicking sclerotic fibroma. ( 29068068 )
2018
7
Pyoderma gangrenosum and erythema elevatum diutinum associated with a high-risk myelodysplastic syndrome: case report. ( 30057994 )
2018
8
Unusual presentation of erythema elevatum diutinum with underlying hepatitis B infection. ( 30063775 )
2018
9
Erythema elevatum diutinum. ( 30066783 )
2018
10
Erythema elevatum diutinum: a case report and review of literature. ( 30074624 )
2018
11
HIV-associated erythema elevatum diutinum: a case report and review of a clinically distinct variant. ( 30142732 )
2018
12
Rare presentation of erythema elevatum diutinum. ( 30238047 )
2018
13
Primary Surgical Treatment of Erythema Elevatum Diutinum. ( 30241974 )
2018
14
Erythema elevatum diutinum a rare and poorly understood cutaneous vasculitis: A single institution experience. ( 30362150 )
2018
15
Erythema Elevatum Diutinum. ( 28183422 )
2017
16
Erythema elevatum diutinum in a healthy child. ( 28397292 )
2017
17
Vesiculobullous variant of erythema elevatum diutinum. ( 28639709 )
2017
18
Late-Stage Erythema Elevatum Diutinum Mimicking a Fibroblastic Tumor: A Potential Pitfall. ( 29293121 )
2017
19
Erythema, Elevatum Diutinum ( 28846276 )
2017
20
A rare case of erythema elevatum diutinum presenting as diffuse neuropathy. ( 28050587 )
2017
21
Erythema elevatum diutinum in Crohn's disease-associated Spondyloarthritis - a rare vasculitis, an unusual association. ( 28917218 )
2017
22
Erythema elevatum diutinum-associated with loss of the uvula. ( 28443312 )
2017
23
Erythema elevatum diutinum involving palms and soles: a case report and literature review. ( 28469800 )
2017
24
Complete resolution of erythema elevatum diutinum using oral sulfasalazine. ( 29469798 )
2017
25
Erythema elevatum diutinum presenting with palmoplantar keratoderma. ( 28512994 )
2017
26
Truncal Erythema Elevatum Diutinum With Elevated Cryoglobulin Level. ( 29901001 )
2017
27
Granuloma Faciale and Erythema Elevatum Diutinum in Relation to Immunoglobulin G4-Related Disease: An Appraisal of 32 Cases. ( 27124923 )
2016
28
Pediatric case of microscopic polyangiitis with skin manifestations resembling vesiculobullous type erythema elevatum diutinum with immunoglobulin A antineutrophil cytoplasmic antibody. ( 27097593 )
2016
29
Erythema elevatum diutinum in acquired immune deficiency syndrome: Can it be an immune reconstitution inflammatory syndrome? ( 27190420 )
2016
30
Erythema elevatum diutinum in association with IgA monoclonal gammopathy: A rare case report. ( 27559509 )
2016
31
Chronic Localized Fibrosing Leukocytoclastic Vasculitis Associated With Lymphedema, Intralymphatic and Intravascular Lymphocytosis, and Chronic Myelogenous Leukemia: A Case Report of Unilateral Erythema Elevatum Diutinum. ( 27930381 )
2016
32
Erythema elevatum diutinum coexisting with ankylosing spondylitis. ( 27708930 )
2015
33
A case of mistaken identity: unilateral erythema elevatum diutinum associated with IgA paraproteinaemia. ( 25754401 )
2015
34
Erythema elevatum diutinum and hypothyroidism: coincidence or causal relationship? ( 26375227 )
2015
35
Erythema elevatum diutinum: an atypical presentation. ( 25521326 )
2015
36
A Case of Erythema Elevatum Diutinum With Pancytopenia: Focus on Dapsone-Induced Hematologic Side Effects and Colchicine as a Safe Treatment Option. ( 26461818 )
2015
37
Erythema elevatum diutinum in association with dermatitis herpetiformis. ( 24616856 )
2014
38
An atypical distribution of erythema elevatum diutinum. ( 24479627 )
2014
39
Erythema Elevatum Diutinum (EED): A Distinctive Vasculitis with Acute-on-Chronic Features. ( 24652434 )
2014
40
Case of Erythema Elevatum Diutinum Associated With IgA Paraproteinemia Successfully Controlled With Thalidomide and Plasma Exchange. ( 25257541 )
2014
41
An unusual case of erythema elevatum diutinum with penile and laryngeal manifestations. ( 24413401 )
2014
42
Nodular Erythema Elevatum Diutinum Mimicking Kaposi's Sarcoma in a Human Immunodeficiency Virus Infected Patient. ( 25484391 )
2014
43
Erythema elevatum diutinum: a review of presentation and treatment. ( 25288365 )
2014
44
An unusual case of Sweet syndrome in a child: overlapping presentation with erythema elevatum diutinum. ( 24521734 )
2014
45
Novel use of topical dapsone 5% gel for erythema elevatum diutinum: safer and effective. ( 23652900 )
2013
46
Erythema elevatum diutinum. ( 23442466 )
2013
47
Atypical erythema elevatum diutinum or extrafacial granuloma faciale? ( 23253514 )
2013
48
Erythema elevatum diutinum. ( 23487831 )
2013
49
Erythema elevatum diutinum: a new vesiculobullous case. ( 24001509 )
2013
50
Associated pyoderma gangrenosum, erythema elevatum diutinum, and Sweet's syndrome: the concept of neutrophilic disease. ( 24073904 )
2013

Variations for Erythema Elevatum Diutinum

Expression for Erythema Elevatum Diutinum

Search GEO for disease gene expression data for Erythema Elevatum Diutinum.

Pathways for Erythema Elevatum Diutinum

GO Terms for Erythema Elevatum Diutinum

Cellular components related to Erythema Elevatum Diutinum according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.1 CD34 CXCL8 F13A1 HBA1 S100A9 TNFRSF1B

Biological processes related to Erythema Elevatum Diutinum according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 neutrophil degranulation GO:0043312 9.78 CD68 PECAM1 S100A9 TNFRSF1B
2 positive regulation of gene expression GO:0010628 9.73 CD34 FOXP3 GATA3 TBX21
3 negative regulation of gene expression GO:0010629 9.71 CD34 FOXP3 GATA3
4 response to virus GO:0009615 9.58 FOXP3 GATA3 TBX21
5 cytokine-mediated signaling pathway GO:0019221 9.56 CXCL8 F13A1 GATA3 TNFRSF1B
6 negative regulation of tumor necrosis factor production GO:0032720 9.55 CD34 FOXP3
7 negative regulation of inflammatory response GO:0050728 9.54 FOXP3 GATA3 TNFRSF1B
8 T cell differentiation GO:0030217 9.52 GATA3 TBX21
9 cytokine production GO:0001816 9.51 FOXP3 S100A9
10 negative regulation of interferon-gamma production GO:0032689 9.49 FOXP3 GATA3
11 positive regulation of interleukin-4 production GO:0032753 9.46 FOXP3 GATA3
12 negative regulation of T-helper 17 cell differentiation GO:2000320 9.32 FOXP3 TBX21
13 lymphocyte migration GO:0072676 9.16 GATA3 TBX21
14 glomerular endothelium development GO:0072011 8.96 CD34 PECAM1
15 negative regulation of interleukin-2 production GO:0032703 8.8 FOXP3 GATA3 TBX21

Sources for Erythema Elevatum Diutinum

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....